Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’...
October 02 2019 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, today announced that the United States Patent and
Trademark Office (USPTO) granted U.S. Patent No. 10,426,754 to
support Anavex’s leading drug candidate, ANAVEX®2-73 (blarcamesine)
for the treatment of Alzheimer’s disease.
Anavex’s newest patent is expected to remain in
force at least until 2037, not including any patent term
extensions. It covers compositions of matter directed to
crystalline ANAVEX®2-73 (blarcamesine), and methods of treating
Alzheimer’s disease using crystalline ANAVEX®2-73 (blarcamesine).
ANAVEX®2-73 (blarcamesine) recently completed a successful Phase 2a
clinical trial for Alzheimer’s disease and is currently in clinical
studies in a larger Phase 2b/3 study for Alzheimer’s disease, among
other studies (NCT03790709). The ‘754 patent adds important
coverage for crystalline ANAVEX®2-73 (blarcamesine) dosage forms
for treating Alzheimer’s disease.
“We are extremely pleased with the continued
development of the patent portfolio for ANAVEX®2-73 (blarcamesine).
This new issuance of the U.S. patent continues to expand the
breadth and depth of our intellectual property and is another step
in the development of a robust patent portfolio relating to
ANAVEX®2-73 (blarcamesine),” said Christopher U. Missling, PhD,
President and Chief Executive Officer of Anavex.
ANAVEX®2-73 (blarcamesine) is an orally
available, small-molecule activator of the sigma-1 receptor which,
data suggest, is pivotal to restoring neural cell homeostasis and
promoting neuroplasticity.1
About Alzheimer’s Disease
Alzheimer's disease is a progressive,
irreversible neurological disease and the most common cause of
dementia. In the U.S., there are over five million individuals
living with Alzheimer's disease and an estimated 50 million people
live with dementia worldwide. Today, there are no commercially
available therapies to address the underlying cause of Alzheimer's.
According to the World Alzheimer Report 2019, the current annual
cost of dementia is estimated at $1 trillion, a figure set to
double by 2030.2
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, pain and various types of
cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine),
recently completed a successful Phase 2a clinical trial for
Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally
available drug candidate that restores cellular homeostasis by
targeting sigma-1 and muscarinic receptors. Preclinical studies
demonstrated its potential to halt and/or reverse the course of
Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited
anticonvulsant, anti-amnesic, neuroprotective and anti-depressant
properties in animal models, indicating its potential to treat
additional CNS disorders, including epilepsy. The Michael J. Fox
Foundation for Parkinson’s Research previously awarded Anavex a
research grant, which fully funded a preclinical study to develop
ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s
disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic
receptors, is a promising preclinical drug candidate demonstrating
disease-modifying activity against the major hallmarks of
Alzheimer’s disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies. In preclinical
trials, ANAVEX®3-71 has shown beneficial effects on
neuroinflammation and mitochondrial dysfunction. Further
information is available at www.anavex.com. You can also connect
with the company
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors & Media:Email:
ir@anavex.com
1 Advances in Experimental Medicine and Biology Volume 964
(2017) Sigma Receptors: Their Role in Disease and as Therapeutic
Targets2
https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2023 to Apr 2024